Suppr超能文献

1996年至2001年间头孢唑兰对各种临床分离株抗菌活性的年度变化——II.革兰氏阴性菌

[Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2001--II. Gram-negative bacteria].

作者信息

Suzuki Yumiko, Nishinari Chisato, Endo Harumi, Hiramatsu Nobuyoshi, Akiyama Kazumitsu, Koyama Tsuneo

机构信息

Section of Studies, Tokyo Clinical Research Center.

出版信息

Jpn J Antibiot. 2003 Aug;56(4):309-35.

Abstract

The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2001 were yearly evaluated and compared with those of other cephems, oxacephems and carbapenems. A total of 3,245 strains in 32 species of Gram-negative bacteria were isolated from the clinical materials annually collected from January to December, and consisted of Moraxella subgenus Branhamella catarrhalis, Escherichia coli, Citrobacter freundii, Citrobacter koseri, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Proteus mirabillis, Proteus vulgaris, Morganella morganii, Providencia spp. (P. alcalifaciens, P. rettgeri, P. stuartii), Pseudomonas aeruginosa, Pseudomonas putida, Burkholderia cepacia, Stenotrophomonas maltophilia, Haemophilus influenzae, Acinetobactor baumannii, Acinetobactor lwoffii, Bacteroides fragilis group (B. fragilis, B. vulgatus, B. distasonis, B. ovatus, B. thetaiotaomicron), and Prevotella spp. (P. melaninogenica, P. intermedia, P. bivia, P. oralis, P. denticola). CZOP possessed stable antibacterial activities against M. (B.) catarrhalis, E. coli, C. freundii, C. koseri, K. pneumoniae, K. oxytoca, E. aerogenes, E. cloacae, S. marcescens, P. mirabilis, P. vulgaris, M. morganii, Providencia spp., P. aeruginosa, and A. lwoffii throughout 6 years. The MIC90 of CZOP against those strains were consistent with those obtained from the studies performed until the new drug application approval. On the other hand, the MIC90 of CZOP against H. influenzae yearly obviously increased with approximately 64-time difference during the study period. The MIC90 of cefpirome, cefepime, and flomoxef against H. influenzae also yearly tended to rise. The present results demonstrated that CZOP had maintained the antibacterial activity against almost Gram-negative strains tested. However, the decrease in antibacterial activities of CZOP against B. cepacia, and H. influenzae was suggested.

摘要

头孢唑兰(CZOP)是一种头孢菌素类药物,对1996年至2001年间分离出的各种临床分离株进行了体外抗菌活性的年度评估,并与其他头孢菌素类、氧头孢烯类和碳青霉烯类药物进行了比较。每年1月至12月从临床材料中分离出32种革兰氏阴性菌的3245株菌株, 包括莫拉菌属(卡他布兰汉菌)、大肠杆菌、弗氏柠檬酸杆菌、科氏柠檬酸杆菌、肺炎克雷伯菌、产酸克雷伯菌、产气肠杆菌、阴沟肠杆菌、粘质沙雷菌、奇异变形杆菌、普通变形杆菌、摩根摩根菌、普罗威登斯菌属(产碱普罗威登斯菌、雷氏普罗威登斯菌、斯氏普罗威登斯菌)、铜绿假单胞菌、恶臭假单胞菌、洋葱伯克霍尔德菌、嗜麦芽窄食单胞菌、流感嗜血杆菌、鲍曼不动杆菌、鲁氏不动杆菌、脆弱拟杆菌群(脆弱拟杆菌、普通拟杆菌、多形拟杆菌、卵形拟杆菌、嗜热栖热菌)和普雷沃菌属(产黑色素普雷沃菌、中间普雷沃菌、二路普雷沃菌、口腔普雷沃菌、牙栖普雷沃菌)。在6年期间,CZOP对卡他莫拉菌(布兰汉菌)、大肠杆菌、弗氏柠檬酸杆菌、科氏柠檬酸杆菌、肺炎克雷伯菌、产酸克雷伯菌、产气肠杆菌、阴沟肠杆菌、粘质沙雷菌、奇异变形杆菌、普通变形杆菌、摩根摩根菌、普罗威登斯菌属、铜绿假单胞菌和鲁氏不动杆菌具有稳定的抗菌活性。CZOP对这些菌株的MIC90与新药申请批准前进行的研究结果一致。另一方面,在研究期间,CZOP对流感嗜血杆菌的MIC90每年明显增加,差异约为64倍。头孢匹罗、头孢吡肟和氟氧头孢对流感嗜血杆菌的MIC90也呈逐年上升趋势。目前的结果表明,CZOP对几乎所有测试的革兰氏阴性菌株都保持了抗菌活性。然而,提示CZOP对洋葱伯克霍尔德菌和流感嗜血杆菌的抗菌活性有所下降。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验